A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Trial Profile

A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Feb 2018 Results evaluating the potential benefit of TA and pre-H ticagrelor treatment in patients enrolled in the ATLANTIC trial published in the American Heart Journal
    • 01 Feb 2018 Results of post hoc analysis from the ATLANTIC study examining whether there is a differential treatment effect of pre-hospital administration of ticagrelor compared with in hospital ticagrelor administration on during and post PCI markers of reperfusion and clinical outcomes by duration of symptom onset to first medical contact (FMC) published in the American Heart Journal
    • 30 Aug 2017 Results (n=1449) assessing association between peri-procedural anticoagulants and clinical outcomes, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top